Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 250 mg Injection (subcutaneous; 50 mg/0.4 mL, 87.5 mg/0.7 mL, 125 mg/mL) |
| Drug Class | Selective T cell costimulation modulators |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA)
- Indicated for the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA)
- Indicated for the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA)
- Indicated for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched
- or 1 allele-mismatched unrelated donor.
Latest News
Summary
- This summary is based on the review of eight systematic review(s)/meta-analysis(es). [1-8]
- Abatacept effectively delays the onset of full-blown rheumatoid arthritis (RA) in at-risk individuals and shows efficacy in reducing disease-related physical limitations; it achieves radiographic non-progression in psoriatic arthritis (PsA) patients, though it is less effective than tumor necrosis factor (TNF) and IL inhibitors for this outcome.
- Compared to TNF inhibitors, abatacept’s efficacy in RA and PsA is not affected by BMI, whereas TNF inhibitors’ effectiveness is BMI-dependent; interleukin (IL) inhibitors inhibitors, unaffected by body mass index (BMI), also outperform abatacept in preventing radiographic progression in PsA.
- Abatacept demonstrates comparable DeltaDAS28 efficacy to adalimumab, certolizumab, etanercept, rituximab, and tofacitinib, showing over a 70% probability of statistical significance against control by Week 6.
- Abatacept demonstrated an acceptable safety profile in PsA and RA patients, with limited significant safety differences compared to other biologic disease-modifying anti-rheumatic drugs (bDMARDs).
- Specific safety data for abatacept in Pediatric Rheumatic Diseases (PiRD) is limited in the reviewed studies.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Orencia (abatacept) Prescribing Information. | 2024 | Bristol-Myers Squibb, Princeton, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| NCCN guidelines for patients: Graft versus host disease | 2021 | NCCN |
| 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis | 2019 | Arthritis Care & Research |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update | 2019 | Annals of the Rheumatic Diseases |